Ronald C. Renaud has served as the president and chief executive officer of Idenix Pharmaceuticals, Inc. since October 2010. Prior to this, Mr. Renaud served as the chief financial officer of Idenix from the time he joined the Company in June 2007 and was additionally appointed chief business officer in June 2010. Mr. Renaud brings a unique mix of skills to this leadership role with his finance experience at public biotechnology companies and on Wall Street, as well as his science background. Prior to joining Idenix, Mr. Renaud served as chief financial officer of Keryx Biopharmaceuticals. Prior to Keryx, he spent several years as a senior biotechnology equity analyst for leading investment banks including Bear Stearns, Schwab SoundView and JP Morgan. Additional industry experience includes Mr. Renaud’s more than five years at Amgen Inc., where he held positions in clinical research, investor relations and finance.
Mr. Renaud holds a Masters in Business Administration from the Marshall School of Business at the University of Southern California and a Bachelor of Arts from St. Anselm College in Manchester, NH.
Daniella Beckman has served as the senior vice president, chief financial officer and treasurer of Idenix since March 2012 and the vice president, chief financial officer and treasurer since June 2011. Ms. Beckman served as the interim chief financial officer and treasurer of Idenix from October 2010 to June 2011 and as the corporate controller of Idenix from March 2008 to October 2010. Before joining Idenix, Ms. Beckman held positions at Coley Pharmaceutical Group, including her role as corporate controller.Prior to Coley, Ms. Beckman held financial positions at Biogen Idec as well as PricewaterhouseCoopers.
Ms. Beckman holds a B.A. from Boston University and is also a Certified Public Accountant (CPA).
Jacques Dumas, Ph.D., has served as Executive Vice President and Chief Scientific Officer since January 2014. Dr. Dumas is trained as a medicinal chemist and brings over 20 years of experience in pharmaceutical discovery and development, supporting a variety of programs in infectious diseases and oncology. He is a co-inventor of two marketed drugs in the field of oncology, Nexavar® and Stivarga®. Prior to joining Idenix, Dr. Dumas served as Vice President and Head of Strategy, Infection Innovative Medicines at AstraZeneca plc since December 2010. In this position, he was responsible for disease area strategy and external collaborations on behalf of AstraZeneca’s small-molecule infectious diseases unit. Prior to that role and between February 2007 and December 2010, Dr. Dumas held the successive positions of Associate Director, Medicinal Chemistry and Emerging Products Director at AstraZeneca. Prior to joining AstraZeneca, Dr. Dumas held several positions at Bayer HealthCare Pharmaceuticals, Inc., a subsidiary of Bayer AG, from 1995 to 2007.
Dr. Dumas received his Ph.D. in Organic Chemistry from Paris 6 University in 1991.
Paul Fanning has served as senior vice president, human resources since January 2008. Paul joined the company as vice president, human resources in March 2004. Prior to joining Idenix, Mr. Fanning was employed by The Foxboro Company and its affiliates from 1984 to 2004, including his role as vice president, human resources at Invensys Process Systems from 2000 to 2004 and as vice president, human resources, Invensys Process Automation from 1998 to 2000.
Mr. Fanning holds an M.B.A. from Babson College and a B.S. from the University of Massachusetts.
Eric Hoffman joined Idenix Pharmaceuticals in January 2011 and currently oversees Business Development, Commercial Operations and Program Management activities, with prior responsibility for leading the Investor Relations and Corporate Communications effort. Prior to Idenix, he worked for four years at Biogen Idec in Investor Relations and Business Development roles. Prior to entering industry, Dr. Hoffman spent six years on Wall Street as an equity research analyst at JPMorgan, Schwab Soundview Capital Markets and Bear Stearns. Before starting on Wall Street in 2001, he was a post-doctoral research scientist in the Department of Immunobiology at Guy’s Hospital in London, studying immune system development. He has authored several book chapters and peer-reviewed papers, including in Cell, Immunity, and Genes & Development.
He holds a Ph.D. in Cellular, Molecular and Developmental Biology from Yale University and a B.S. in Biology from Trinity University.
Douglas Mayers, M.D., has served as the executive vice president and chief medical officer at Idenix since January 2007. Prior to joining Idenix, Dr. Mayers was International Head/Vice President, Therapeutic Area of Virology with Boehringer Ingelheim for five years and was responsible for the strategic coordination of all HIV and hepatitis clinical trials in phases I through IV. Prior to joining industry, Dr. Mayers conducted clinical trials in HIV research during his seventeen years in the Navy and his subsequent three years as the Head of Infectious Diseases with Henry Ford Hospital. Board certified in internal medicine and infectious diseases, Dr. Mayers completed his M.D. at the University of Pennsylvania. Dr. Mayers remains in the Navy Reserves and currently holds the rank of Captain. Dr. Mayers also serves as the Chairperson of the National Institutes of Health’s AIDS Discovery and Development of Therapeutics Study Section.
Adel Moussa, Ph.D., has served as vice president, CMC at Idenix Pharmaceuticals since March 2008 and executive director of chemical development since March 2007. Dr. Moussa joined Idenix in March 2002 as director of process research and development and became senior director in February 2005. Before joining Idenix, Dr. Moussa was employed by Johnson Matthey from 1993 to 2002 as associate director of chemistry and Covalent Associates from 1991 to 1993 as senior scientist. Before working in the pharmaceutical industry, Dr. Moussa was assistant professor at the University of Alexandria, Egypt.
Dr. Moussa holds a Ph.D. in organic chemistry from Northeastern University and a bachelor’s and master’s degree in chemistry from the University of Alexandria, Egypt.
Maria Stahl has served as the senior vice president and general counsel at Idenix since October 2010. Ms. Stahl rejoins Idenix after serving as general counsel at Zipcar, Inc. where she was responsible for all legal matters relating to the company. Prior to joining Zipcar, Ms. Stahl was vice president and associate general counsel at Idenix, where she was primarily responsible for public company reporting, corporate governance, Idenix’s intellectual patent portfolio and other legal matters. Ms. Stahl also served as vice president and corporate counsel of Capital Crossing Bank, where she oversaw the sale of the bank to Lehman Brothers Bank in 2007. Prior to that, Ms. Stahl was a junior partner at Wilmer Hale where she represented public and private company clients in a variety of matters.
Ms. Stahl holds a B.A. from Providence College and a J.D. from Yale Law School.